Register Login

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (KNSA)

SymbolKNSA
NameKINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address105 PICCADILLY,SECOND FLOOR, LONDON, W1J 7NJ, Bermuda
Telephone+44 781 431 - 9100
Fax—
Email—
Websitehttps://www.kiniksa.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001730430
Description

Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksas portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.

Additional info from NASDAQ:
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.

Additional info from NASDAQ:
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksas portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.

2026-06-02 20:52

Quart Barry D 🟡 adjusted position in 14.2K shares (3 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) at $48.38 Transaction Date: May 29, 2026 | Filing ID: 000012

Read more
2026-06-02 20:51

Popovits Kimberly J 🟡 adjusted position in 14.2K shares (3 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) at $48.38 Transaction Date: May 29, 2026 | Filing ID: 000002

Read more
2026-06-02 20:50

Patel Sanj K 🟡 adjusted position in 0 shares (1 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) Transaction Date: Jun 01, 2026 | Filing ID: 000012

Read more
2026-06-02 20:46

Malley Thomas 🟡 adjusted position in 14.2K shares (3 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) at $48.38 Transaction Date: May 29, 2026 | Filing ID: 000002

Read more
2026-06-02 20:44

Levy Richard S 🟡 adjusted position in 14.2K shares (3 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) at $48.38 Transaction Date: May 29, 2026 | Filing ID: 000004

Read more
2026-06-02 20:42

Cole G Bradley 🟡 adjusted position in 14.2K shares (3 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) at $48.38 Transaction Date: May 29, 2026 | Filing ID: 000002

Read more
2026-06-02 20:30

BAKER BROS. ADVISORS LP 🟢 acquired 85.1K shares (2 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) at $48.38 ($3.5M) Transaction Date: May 29, 2026 | Filing ID: 253615

Read more
2026-05-29 20:35

(99% Neutral) KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (KNSA) Announces Regulatory Update

Read more
2026-05-29 20:01

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Read more
2026-05-26 20:55

(99% Neutral) KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (KNSA) Announces Business Combination

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07288216 Transition to KPL-387 Monotherapy Dosing & Administration Study Phase2 Recurrent Pericarditis Recruiting 2026-03-25 2029-12-31 ClinicalTrials.gov
NCT07010159 Phase 2/3 Study of KPL-387 in Recurrent Pericarditis Phase2 Pericarditis Recruiting 2025-07-25 2029-12-31 ClinicalTrials.gov
NCT06531395 A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With … Phase2 Sjögrens Disease Terminated 2024-07-17 2025-05-01 ClinicalTrials.gov
NCT05198310 Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Partic… Phase2 Arthritis, Rheumatoid Completed 2021-12-14 2024-05-06 ClinicalTrials.gov
NCT04687358 REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adul… — Recurrent Pericarditis Active_Not_Recruiting 2021-03-16 2029-03-01 ClinicalTrials.gov
NCT04463004 Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pne… Phase2 COVID-19 Completed 2020-09-02 2020-11-30 ClinicalTrials.gov
NCT04447469 Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona… Phase2 COVID Completed 2020-07-28 2022-01-14 ClinicalTrials.gov
NCT04492514 Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pne… Phase2 COVID 19 Completed 2020-05-20 2020-11-16 ClinicalTrials.gov
NCT04399980 Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pne… Phase2 COVID 19 Completed 2020-05-20 2021-04-23 ClinicalTrials.gov
NCT04497662 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… Phase1 Healthy Volunteers Completed 2019-10-22 2021-03-02 ClinicalTrials.gov
NCT03858634 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing… Phase2 Chronic Idiopathic Urticaria Completed 2019-05-29 2020-06-08 ClinicalTrials.gov
NCT03816891 Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reduci… Phase2 Prurigo Nodularis Completed 2019-03-11 2023-08-24 ClinicalTrials.gov
NCT03737110 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants… Phase3 Recurrent Pericarditis Completed 2019-01-07 2022-06-30 ClinicalTrials.gov
NCT03827018 KPL-301 for Subjects With Giant Cell Arteritis Phase2 Giant Cell Arteritis Completed 2018-09-20 2020-11-25 ClinicalTrials.gov
NCT03980522 A Pilot Study of KPL-914 in Recurrent Pericarditis Phase2 Recurrent Pericarditis Completed 2018-01-24 2019-05-17 ClinicalTrials.gov
Total clinical trials: 15
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
Placebo Other Phase PHASE2 COVID 19 COMPLETED NCT04492514
Mavrilimumab Other Phase PHASE2 COVID 19 COMPLETED NCT04492514
Placebo Other Phase PHASE2 Sjögrens Disease TERMINATED NCT06531395
Abiprubart Other Phase PHASE2 Sjögrens Disease TERMINATED NCT06531395
Matching Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04497662
KPL-404 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04497662
Placebos Other Phase PHASE2 COVID 19 COMPLETED NCT04399980
Mavrilimumab Other Phase PHASE2 COVID 19 COMPLETED NCT04399980
KPL-914 Other Phase PHASE2 Recurrent Pericarditis COMPLETED NCT03980522
Placebos Other Phase PHASE2 COVID-19 COMPLETED NCT04463004
Mavrilimumab Other Phase PHASE2 COVID-19 COMPLETED NCT04463004
Placebo Other Phase PHASE3 Recurrent Pericarditis COMPLETED NCT03737110
Rilonacept Other Phase PHASE3 Recurrent Pericarditis COMPLETED NCT03737110
Placebo Other Phase PHASE3 Recurrent Pericarditis COMPLETED NCT03737110
Rilonacept Other Phase PHASE3 Recurrent Pericarditis COMPLETED NCT03737110
Placebo Other Phase PHASE3 Recurrent Pericarditis COMPLETED NCT03737110
Rilonacept Other Phase PHASE3 Recurrent Pericarditis COMPLETED NCT03737110
prednisone Other Phase PHASE2 Giant Cell Arteritis COMPLETED NCT03827018
placebo Other Phase PHASE2 Giant Cell Arteritis COMPLETED NCT03827018
mavrilimumab Other Phase PHASE2 Giant Cell Arteritis COMPLETED NCT03827018
Placebo Other Phase PHASE2 COVID COMPLETED NCT04447469
mavrilimumab Other Phase PHASE2 COVID COMPLETED NCT04447469
Placebo Other Phase PHASE2 Chronic Idiopathic Urticaria COMPLETED NCT03858634
KPL-716 Other Phase PHASE2 Chronic Idiopathic Urticaria COMPLETED NCT03858634
Placebo Other Phase PHASE2 Arthritis, Rheumatoid COMPLETED NCT05198310
KPL-404 Other Phase PHASE2 Arthritis, Rheumatoid COMPLETED NCT05198310
Placebo Other Phase PHASE2 Prurigo Nodularis COMPLETED NCT03816891
Vixarelimab Other Phase PHASE2 Prurigo Nodularis COMPLETED NCT03816891
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Placebo Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-387 Other Phase PHASE2 Pericarditis RECRUITING NCT07010159
KPL-914 DRUG Phase PHASE2 Recurrent Pericarditis COMPLETED NCT03980522
Rilonacept DRUG Phase PHASE3 Recurrent Pericarditis COMPLETED NCT03737110
KPL-387 DRUG Phase PHASE2 Recurrent Pericarditis RECRUITING NCT07288216
Abiprubart DRUG Phase PHASE2 Sjögrens Disease TERMINATED NCT06531395
Placebo DRUG Phase PHASE3 Recurrent Pericarditis COMPLETED NCT03737110
mavrilimumab DRUG Phase PHASE2 COVID COMPLETED NCT04447469
Total products: 112